In the typical regulatory scheme a franchised monopoly has little incentive to reduce costs. This article proposes a mechanism in which the price the regulated firm receives depends on the costs of identical firms. In equilibrium each firm chooses a socially efficient level of cost reduction. The mechanism generalizes to cover heterogeneous firms with observable differences. Medicare's prospective reimbursement of hospitals by using diagnostically related groups is a scheme very similar to the one outlined here.
No takes yet. Share an insight, caveat, or question.
Andrei Shleifer (1985) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: